ProCE Banner Activity

Individualizing CLL Therapy: Second-Line Treatment and Beyond

Slideset

In these downloadable slides, experts discuss data driving treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia.

Released: September 13, 2024

Expiration: September 12, 2025

Share

Faculty

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Farrukh T. Awan

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Shuo Ma

Shuo Ma, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC in partnership with CLL Society

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc.; AstraZeneca; Beigene, Ltd.; and Bristol Myers Squibb.

AbbVie Inc.

AstraZeneca

BeiGene, Ltd.

Bristol Myers Squibb

Partners

CLL Society

ProCE Banner